 |
- goat polyclonal IgG, 200 µg/ml
- epitope mapping at the C-terminus of SYT of human origin
- recommended for detection of SYT of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including equine, canine and porcine
- blocking peptide, sc-8820 P
- TransCruz reagent for Gel Supershift and ChIP applications, sc-8820 X, 200 µg/0.1 ml
|
|
| |
Ordering Information
Recommended Support Products:
(click button of application of choice)
SYT Background Information
The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1-5, are transcriptional repressors that contain a repressor domain in their carboxy termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SYT-SSX chimeras are detected in most synovial sarcomas. Synovial sarcomas are responsible for up to 10% of soft issue sarcomas and are histologically characterized as either biphasic or monophasic. Genetic analysis indicates that biphasic synovial sarcomas contain SYT-SSX1 fusions, whereas SYT-SSX2 fusions are found in monophasic synovial sarcomas, providing additional distinguishing characterization of these subtypes. |
|
|
SYT (C-19)
Click on image to enlarge
|
SYT (C-19): sc-8820. Western blot analysis of SYT expression in non-transfected 293T: sc-117752 (A), human SYT transfected 293T: sc-178011 (B) whole cell lysates and HeLa (C) nuclear extract. |
|
Download
|
|
